Pre-market
Loading marketsโ€ฆ

Advertisement

Stocks

What's Going On With Eupraxia Pharmaceuticals Inc Stock Thursday?

By Wealth Awesome -

Follow live quotes and coverage.

Stocks & ETFs:EPRX.TO

Get EPRX alerts:

Photos provided by Pexels

Eupraxia Pharmaceuticals Inc. has seen notable fluctuations in its stock price this week, reflecting investor sentiment amidst recent company developments.

Eupraxia Pharmaceuticals Inc. (EPRX.TO) faced a challenging week, with its stock price declining by 7.91% over the past five days. As of the latest trading session, the stock closed at C$9.10, down 1.99% for the day. This movement comes against a backdrop of recent public offerings and financial reporting that have influenced market perception.

Investor takeaway: Investors should consider the implications of Eupraxia's recent public offerings and financial performance when evaluating the stock's potential. The company's focus on developing innovative therapies may offer long-term growth opportunities, but the current volatility suggests caution in the short term.

Advertisement

Eupraxia Pharmaceuticals Inc

EPRX.TO

Full stock page โ†’

EPRX.TO

Eupraxia Pharmaceuticals Inc

Source:WealthAwesomeWealthAwesome
โ†“ $1.16 (-10.35%)
120 day period
$8.22$9.71$11.21Mar 4May 29Aug 24

Market cap

$664.04M

52W high

$12.86

52W low

$6.95

1W change

+5.79%

Beta

1.50

Analyst Price Targets

Based on analyst covering EPRX

๐Ÿ“ˆ

Wall Street analysts forecast EPRX stock price to rise 59.2% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$16.00

+59.2% Upside

Current Price

C$10.05

Last close

Compare analyst targets across the TSX & TSXV โ†’

Analyst ratings and price targets are updated periodically. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on EPRX's historical volatility

HistoricalForecast68%95%
C$4.62C$7.87C$11.13C$14.39C$17.64C$20.90TodayApr 16Jun 19Aug 24Oct 6Nov 19Jan 1

30-Day Vol

60.6%

Annualized

90-Day Vol

56.8%

Annualized

Trend (90d)

-6.2%

Annualized drift

90d Mean

C$9.83

Expected price

HorizonExpected68% Range (1ฯƒ)
30 trading daysC$9.98C$8.09 โ€“ C$12.30
60 trading daysC$9.90C$7.37 โ€“ C$13.31
90 trading daysC$9.83C$6.84 โ€“ C$14.12

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯƒ, 95% band = ยฑ2ฯƒ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Advertisement

Eupraxia's Stock Declines 7.91% This Week Amidst Market Volatility.

With a market cap of approximately C$558.5 million and a beta of 1.50, Eupraxia's stock shows higher volatility compared to the broader market, indicating potential risks for investors.

Bull case

The recent public offering raised about US$63.2 million, which could enhance Eupraxia's financial stability and support ongoing clinical trials for its lead product, EP-104GI. Analysts remain optimistic, with an average price target of C$16.33, suggesting significant upside potential from current levels.

Bear case

However, the stock's recent performance, including a year-to-date decline of nearly 20%, raises concerns about market confidence in Eupraxia's growth trajectory. The company's negative profit margin and return on equity may deter risk-averse investors.

Recent Price Action

Advertisement

Eupraxia Pharmaceuticals Inc. (EPRX.TO) has seen a downward trend this week, with its stock price closing at C$9.10, reflecting a 1.99% decline on the day and a 7.91% drop over the past week. This decline is part of a broader trend, as the stock has decreased by 10.37% in the past month and nearly 20% year-to-date.

Company News and Developments

Despite the recent downturn in stock price, Eupraxia has been active in the capital markets. The company recently completed a public offering, raising approximately US$63.2 million to support its clinical programs. This financing could provide the necessary funds for further development of its lead product, EP-104GI, which aims to address significant medical needs.

Technical Picture

From a technical standpoint, Eupraxia's stock is currently trading just below its 50-day moving average of C$9.13 and significantly below its 200-day moving average of C$9.73. The stock's 52-week range has been between C$6.94 and C$12.86, indicating it is currently near the lower end of this range. The recent trading volume of 79,179 shares represents a 1.15x increase compared to the 20-day average volume of 63,216 shares, suggesting increased trading activity.

Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile โ†’

โœ… Reviewed by Certified Financial Professionals

This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

๐Ÿ“Š Data AccuracyVerified sources
๐Ÿ‡จ๐Ÿ‡ฆ Canadian FocusLocal expertise
๐Ÿ” Fact-CheckedEditorial review

โš ๏ธ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: July 30, 2026
Last Updated: July 30, 2026
PARTNER SPOTLIGHT

Blue Cross Lifeยฎ Term Life Insurance

Affordable term life coverage in Canada โ€” get a free quote in seconds, no credit card required.

  • โœ“Coverage from $100,000 to $5 million, terms of 10โ€“30 years
  • โœ“10% off first-year premiums when couples apply together
  • โœ“Fully digital application โ€” many qualify without a medical exam

Sponsored links

Advertisement